Conditions: Psoriasis
Keywords: Psoriasis Topical etanercept clobetasol propionate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 592
Healthy volunteers: no

Brief summary:
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with etanercept monotherapy, as measured by PASI 75 at Week 12.

Detailed description:

Arms:
arm 1: Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24) arm 2: Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks

Interventions: intervention 1: 1=Etanercept intervention 2: 2=Clobetasol propionate foam
Intervention descriptions: intervention 1: 50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks. intervention 2: 0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses

Protocol document: